Cereno, Abbott Team Up to Measure Lung Blood Pressure in New Trial

Cereno, Abbott Team Up to Measure Lung Blood Pressure in New Trial

303707

Cereno, Abbott Team Up to Measure Lung Blood Pressure in New Trial

Cereno Scientific is planning to begin a Phase 2 clinical trial of CS1 — the company’s lead therapy candidate for pulmonary arterial hypertension (PAH) — this September, following clearance from the U.S. Food and Drug Administration (FDA). The upcoming trial will use Abbott‘s CardioMEMS HF System, a wireless, implantable monitor that continuously measures pulmonary arterial pressure, or the blood pressure in the arteries of the lungs, per a new agreement between the two companies. “We…

You must be logged in to read/download the full post.